News & Trends - MedTech & Diagnostics
MedTech giant unveils plans for digital centres after latest acquisition
MedTech & Diagnostics News: A new strategic acquisition signifies a major leap forward for the medtech industry. Embarking on an exciting journey by establishing a series of Digital Excellence Centres (DECs), Olympus is acquiring London-based Odin Vision, a cloud-AI endoscopy company known for its exceptional computer-aided detection/diagnostic solutions and innovative cloud-enabled applications.
With the integration of Odin Vision’s expertise, Olympus is now on the brink of delivering on the promise of AI-powered real-time diagnosis and minimally invasive treatment for chronic diseases. This breakthrough has the potential to elevate the standard of care across various medical specialties, ultimately leading to improved patient outcomes.
The collaboration between Olympus and Odin Vision is poised to shape the future of endoscopy, envisioning an intelligent ecosystem that benefits both patients and healthcare providers. By combining the strength of Olympus’ core endoscopy portfolio with Odin Vision’s digital solutions, the company plans to gather and analyse procedural, clinical, and medical device data in real time.
Powered by a state-of-the-art digital platform utilising the latest AI algorithms and software, Olympus aims to provide healthcare professionals with clinical and operational solutions designed to alleviate administrative and cognitive burdens, while simultaneously enhancing operational efficiency. These advancements will prove invaluable to healthcare institutions striving to elevate the level of care they offer.
Shawn LaRocco, Global VP Customer Solutions at Olympus, expressed the company’s dedication to spearheading the development of intelligent integrated solutions and insights in the healthcare sector. Recognising the importance of collaboration, LaRocco emphasised Olympus’ eagerness to partner with trailblazers like Odin Vision who share their passion for innovation.
To realise this ambitious commercial strategy, Olympus plans to establish DECs worldwide, with London serving as the first hub due to the foundation laid by the acquisition of Odin Vision. Alongside their existing R&D sites in Hamburg, Boston, and Tokyo, Olympus will establish DECs that push the boundaries of creative innovation. There are also future possibilities of expanding the DEC across other countries.
Peter Mountney, CEO of Odin Vision, expressed his excitement about leading Olympus’ plans for the first DECs. Mountney highlighted the goal of empowering clinicians to deliver exceptional care and outcomes to patients through the utilisation of state-of-the-art digital and AI tools.
Karsten Klose, Global Head of Digital at Olympus, further emphasised the company’s vision for the future. Klose stated that establishing DECs around the world would provide Olympus with access to crucial talent and foster partnerships with start-ups and other companies that, like Odin Vision, are at the forefront of creative innovation.
With Olympus’ relentless pursuit of excellence and the integration of Odin Vision’s novel technology, the stage is set for a new era in healthcare.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics
Government’s rejection of COVID Royal Commission a stark contrast to the UK and NZ
The Albanese government has dismissed the Senate legal and constitutional committee’s proposal for a COVID-19 pandemic royal commission with one […]
MoreNews & Trends - Biotechnology
AusBiotech and MTPConnect unite for landmark Summit on the nation’s biotech and medtech future
AusBiotech and MTPConnect have announced an ambitious new collaboration to host Australia’s first National Biotech and Medtech Development and Commercialisation […]
MoreNews & Trends - Pharmaceuticals
Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients: New study
Pharma News: New research from the led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) […]
More